

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1 - 30 (cancelled)

1 31 (currently amended): A method for treating an ophthalmic disorder in a
2 mammal, said method comprising administering to the eye of said mammal a lipid formulation,
3 said lipid formulation comprising:
4 a lipid phase, said lipid phase comprising a phospholipid ~~neutral lipid~~ and a
5 modifying agent, wherein said modifying agent is a member selected from the group consisting
6 of cationic lipids and mucoadhesive compounds;
7 an aqueous phase; and
8 a therapeutic agent, wherein said therapeutic agent in said lipid formulation is
9 useful for treating said ophthalmic disorder;
10 wherein said lipid formulation comprises about 0.001 to about 10.000 wt % of
11 said lipid phase and about 90.000 wt % to about 99.999 wt % of said aqueous phase, and wherein
12 said lipid phase comprises 0.01 to 10 wt% phospholipid, 0.1 to 10 wt % modifying agent and 0.1
13 to 10 wt% antioxidant.

1 32 (original): The method in accordance with claim 31, wherein said ophthalmic
2 disorder is post-operative pain.

1 33 (original): The method in accordance with claim 31, wherein said ophthalmic
2 disorder is ocular inflammation.

1 34 (currently amended): The method in accordance with claim 33, wherein said
2 ocular inflammation results from a member selected from the group consisting of iritis,

3 conjunctivitis, seasonal allergic conjunctivitis, acute and chronic endophthalmitis, anterior
4 uveitis, uveitis associated with systemic diseases, posterior segment uveitis, chorioretinitis, pars
5 planitis, ~~masquerade syndromes including~~ ocular lymphoma, pemphigoid, scleritis, keratitis,
6 severe ocular allergy, corneal abrasion and blood-aqueous barrier disruption.

1 35 (original): The method in accordance with claim 31, wherein said ophthalmic
2 disorder is post-operative ocular inflammation.

1 36 (original): The method in accordance with claim 35, wherein said post-
2 operative ocular inflammation results from a member selected from the group consisting of
3 photorefractive keratectomy, cataract removal surgery, intraocular lens implantation and radial
4 keratotomy.

1 37 (original): The method in accordance with claim 31, wherein said ophthalmic
2 disorder is a fungal or bacterial infection.

1 38 (original): The method in accordance with claim 31, wherein said ophthalmic
2 disorder is herpes ophthalmicus.

1 39 (original): The method in accordance with claim 31, wherein said ophthalmic
2 disorder is endophthalmitis.

1 40 (original): The method in accordance with claim 31, wherein said ophthalmic
2 disorder is intraocular pressure.

1 41 (original): The method in accordance with claim 31, wherein said therapeutic
2 agent is diclofenac.

1 42 (original): The method in accordance with claim 41, wherein said diclofenac
2 is diclofenac sodium.

1 43 (currently amended): A method for treating or preventing ocular
2 inflammation, paracentesis-induced miosis, cystoid macular edema and mydriasis, said method

3 comprising administering a therapeutically effective amount of one or more non-steroidal anti-
4 inflammatory drugs encapsulated or contained within a liposome formulation, said liposome
5 formulation comprising 0.001 to 10.000 wt% lipid phase, and 90.000 to 99.999 wt% aqueous
6 phase, wherein said lipid phase comprises 0.01 to 10 wt% phospholipid, 0.1 to 10% modifying
7 agents and 0.1 to 10 wt% antioxidant.

1 44 (original): The method in accordance with claim 43, wherein said liposome
2 formulation is applied topically, resulting in the transcorneal or transscleral passage or
3 introduction of one or more non-steroidal anti-inflammatory drugs into the eye.

1 45 (currently amended): The method in accordance with claim 43, wherein said
2 lipid phase further comprises 0.0 to 90.0 wt% of one or more active agents, ~~10.0 to 100.0 wt%~~
3 ~~phospholipid, 0.0 to 20.0 wt% antioxidant, and 0.0 to 20% modifying agents~~; and said aqueous
4 phase comprises 0.0 to 10.0 wt% one or more active agents, 0.0 to 5.0 wt% anti-microbial
5 preservative, and 90.0 to 100.0 wt% aqueous solution.

1 46 (original): The method in accordance with claim 45, wherein said active
2 agent(s) are non-steroidal anti-inflammatory drugs.

1 47 (original): The method in accordance with claim 46, wherein said non-
2 steroidal anti-inflammatory drugs are selected from the group consisting of ketoprofen,
3 flurbiprofen, ibuprofen, diclofenac, ketorolac, nepafenac, amfenac and suprofen.

1 48 (original): The method in accordance with claim 47, wherein said non-steroidal
2 anti-inflammatory drug is diclofenac.

1 49 (currently amended): The method in accordance with claim 43, wherein said
2 ocular inflammation is a symptom of iritis, conjunctivitis, seasonal allergic conjunctivitis, post-
3 operative inflammation, acute and chronic endophthalmitis, anterior uveitis, uveitis associated
4 with systemic diseases, posterior segment uveitis, chorioretinitis, pars planitis, ~~masquerade~~

5 ~~syndromes including~~ ocular lymphoma, pemphigoid, scleritis, keratitis, severe ocular allergy,
6 corneal abrasion, blood-aqueous barrier disruption or ocular trauma.

1 50 (original): The method in accordance with claim 49, wherein said post-
2 operative inflammation is caused by photorefractive keratectomy, cataract removal surgery,
3 intraocular lens implantation or radial keratotomy.

51 - 52 (cancelled)